DB15846InvestigationalVaccines
Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. This adjuvant is designed to circumvent... This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants.
- Code names
- Covax-19™
What you can answer from here — as of September 18, 2020
Which companies are running trials of Covax-19™, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account